

# EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care

CME  
Certified

Eat, Drink, and Educate - Join Us for a Light Snack and Timely Discussion!

**Sunday, September 23, 2018**

4:00 – 5:30 PM EDT

**107 MTCC North Building**  
Metro Toronto Convention Centre  
Toronto, Canada

## Chair



**Pasi Jänne, MD, PhD**  
Harvard Medical School  
Lowe Center for Thoracic Oncology  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA

## Faculty



**David Planchard, MD, PhD**  
Gustave Roussy  
Villejuif, France



**Howard (Jack) West, MD**  
Swedish Cancer Institute  
Global Resource for Advancing  
Cancer Education (GRACE)  
Seattle, Washington, USA

# EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care

## Agenda

- 4:00 PM** ● **Welcome & Introduction**  
- Pasi Jänne, MD, PhD
- 4:05 PM** ● **Exploring Our Therapeutic Options in the First-Line: What's New?**  
- Pasi Jänne, MD, PhD
- 4:20 PM** ● **Assessing the Impact of the Latest Data on Practice**  
- Entire Panel
- 4:35 PM** ● **Controversies in First-Line Management of EGFR-Mutant NSCLC**  
- Entire Panel
- 5:00 PM** ● **Current and Evolving Treatments: Cases in Point**  
- Entire Panel
- 5:25 PM** ● **Concluding Remarks and Ask the Faculty**  
- Pasi Jänne, MD, PhD

## Learning Objectives

- Evaluate key clinical data on the use of current and emerging first-line targeted therapy for EGFR-mutant NSCLC
- Recognize the potential impact these clinical-trial data may have on current and future first-line treatment options for EGFR-mutant advanced NSCLC
- Translate recent clinical-trial data on first-line treatment options for EGFR-mutant advanced NSCLC to patient management

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

This activity is supported by an educational grant from AstraZeneca.

Please contact [webmaster@peercme.com](mailto:webmaster@peercme.com) for more information.

© 2010-2018, PeerVoice